Resource StructureDefinition/FHIR Server from package au.csiro.fhir.logical-models#current (234 ms)

Package	au.csiro.fhir.logical-models
Type	StructureDefinition
Id	Id
FHIR Version	R4
Source	https://aehrc.csiro.au/fhir/logical-models/https://build.fhir.org/ig/aehrc/logical-model-web/StructureDefinition-AdverseReactionRisk.html
Url	https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRisk
Version	0.0.1
Status	draft
Date	2023-09-11T00:54:09+10:00
Name	AdverseReactionRisk
Title	Adverse Reaction Risk
Experimental	False
Realm	au
Description	The Adverse Reaction Risk Logical Model Mindmap is shown below. Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance. **Purpose** To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances. **Misuse** Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose. Not to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. Not to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified. Not to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. Not to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose. Not to be used for recording failed therapy. Not to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion. Not to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions. **Considerations** Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening: - immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or - non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities. In clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient. Where a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT. Identification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures. This archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype. Use to record information about the positive presence of the risk of an adverse reaction: - to support the direct clinical care of an individual; - as part of a managed adverse reaction or allergy/intolerance list; - to support the exchange of information about the propensity and events related to adverse reactions; - to inform adverse reaction reporting; and - to assist with computerised knowledge-based activities such as clinical decision support and alerts. The risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing.
Type	https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRisk
Kind	logical

Resources that use this resource

StructureDefinition
https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRiskAUCDI	Adverse Reaction Risk AUCDI

Resources that this resource uses

StructureDefinition
https://aehrc.csiro.au/fhir/logical-models/AdverseReactionEvent	Adverse Reaction Event

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: StructureDefinition AdverseReactionRisk

Name	Flags	Card.	Type	Description & Constraints
AdverseReactionRisk	S	0..*	Base	Adverse Reaction Risk Instances of this logical model are not marked to be the target of a Reference
Protocol	S	0..1	BackboneElement	Protocol
Lastupdated	S	0..1	dateTime	Last updated
Extension	S	0..1	Reference()	Extension
Data	S	0..1	BackboneElement	Data
Substance	S	1..1	CodeableConcept	Substance
Activeinactivestatus	S	0..1	Coding	Activeinactivestatus
Verificationstatus	S	0..1	Coding	Verification status
Criticality	S	0..1	CodeableConcept	Criticality
Category	S	0..1	CodeableConcept	Category
Onsetoflastreaction	S	0..1		Onset of last reaction
Onsetoflastreaction			dateTime
Onsetoflastreaction			string
Onsetoffirstreaction	S	0..1		Onset of first reaction
Onsetoffirstreaction			dateTime
Onsetoffirstreaction			string
Reactionmechanism	S	0..1	CodeableConcept	Reaction mechanism
Reactioneventsummary	S	0..*	Reference(Adverse Reaction Event)	Reaction event summary
Comment	S	0..1	string	Comment
Documentation for this format

Source

{
  "resourceType" : "StructureDefinition",
  "id" : "AdverseReactionRisk",
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: StructureDefinition AdverseReactionRisk</b></p><a name=\"AdverseReactionRisk\"> </a><a name=\"hcAdverseReactionRisk\"> </a><a name=\"AdverseReactionRisk-en-US\"> </a><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" style=\"border: 0px #F0F0F0 solid; font-size: 11px; font-family: verdana; vertical-align: top;\"><tr style=\"border: 1px #F0F0F0 solid; font-size: 11px; font-family: verdana; vertical-align: top\"><th style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views\" title=\"The logical name of the element\">Name</a></th><th style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views\" title=\"Information about the use of the element\">Flags</a></th><th style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views\" title=\"Minimum and Maximum # of times the element can appear in the instance\">Card.</a></th><th style=\"width: 100px\" class=\"hierarchy\"><a href=\"https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views\" title=\"Reference to the type of the element\">Type</a></th><th style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views\" title=\"Additional information about the element\">Description &amp; Constraints</a><span style=\"float: right\"><a href=\"https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views\" title=\"Legend for this format\"><img src=\"data:image/png;base64,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\" alt=\"doco\" style=\"background-color: inherit\"/></a></span></th></tr><tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck1.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_element.gif\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Element\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk\" title=\"Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance.\">AdverseReactionRisk</a><a name=\"AdverseReactionRisk\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..*</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://build.fhir.org/types.html#Base\">Base</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Adverse Reaction Risk<br/><span style=\"font-weight:bold\">Instances of this logical model are not marked to be the target of a Reference</span><br/></td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck11.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Protocol\" title=\"@ internal @\">Protocol</a><a name=\"AdverseReactionRisk.Protocol\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#BackboneElement\">BackboneElement</a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Protocol</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck110.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vline.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_primitive.png\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Primitive Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Protocol.Lastupdated\" title=\"Date when the propensity or the reaction event was updated.\">Lastupdated</a><a name=\"AdverseReactionRisk.Protocol.Lastupdated\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#dateTime\">dateTime</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Last updated</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck100.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vline.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin_end.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_reference.png\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Reference to another Resource\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Protocol.Extension\" title=\"Additional information required to capture local content or to align with other reference models/formalisms.\">Extension</a><a name=\"AdverseReactionRisk.Protocol.Extension\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/references.html\">Reference</a>()</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Extension</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck01.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin_end.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data\" title=\"@ internal @\">Data</a><a name=\"AdverseReactionRisk.Data\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#BackboneElement\">BackboneElement</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Data</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Substance\" title=\"Identification of a substance, or substance class, that is considered to put the individual at risk of an adverse reaction event.\">Substance</a><a name=\"AdverseReactionRisk.Data.Substance\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">1..1</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#CodeableConcept\">CodeableConcept</a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Substance</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Activeinactivestatus\" title=\"Status about whether the adverse reaction risk statement is active or inactive.\">Activeinactivestatus</a><a name=\"AdverseReactionRisk.Data.Activeinactivestatus\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#Coding\">Coding</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Activeinactivestatus</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Verificationstatus\" title=\"Assertion about the certainty of the propensity, or potential future risk, of the identified 'Substance' to cause a reaction.\">Verificationstatus</a><a name=\"AdverseReactionRisk.Data.Verificationstatus\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#Coding\">Coding</a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Verification status</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Criticality\" title=\"An indication of the potential for critical system organ damage or life threatening consequence.\">Criticality</a><a name=\"AdverseReactionRisk.Data.Criticality\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#CodeableConcept\">CodeableConcept</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Criticality</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Category\" title=\"Category of the identified 'Substance'.\">Category</a><a name=\"AdverseReactionRisk.Data.Category\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#CodeableConcept\">CodeableConcept</a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Category</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck011.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_choice.gif\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Choice of Types\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Onsetoflastreaction\" title=\"The date and/or time of the onset of the last known occurrence of a reaction event.\">Onsetoflastreaction</a><a name=\"AdverseReactionRisk.Data.Onsetoflastreaction\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Onset of last reaction</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0110.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vline.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_primitive.png\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Primitive Data Type\" class=\"hierarchy\"/> <span title=\"Base StructureDefinition for dateTime Type: A date, date-time or partial date (e.g. just year or year + month).  If hours and minutes are specified, a time zone SHALL be populated. The format is a union of the schema types gYear, gYearMonth, date and dateTime. Seconds must be provided due to schema type constraints but may be zero-filled and may be ignored.                 Dates SHALL be valid dates.\">Onsetoflastreaction</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#dateTime\">dateTime</a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0100.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vline.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin_end.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_primitive.png\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Primitive Data Type\" class=\"hierarchy\"/> <span title=\"Base StructureDefinition for string Type: A sequence of Unicode characters\">Onsetoflastreaction</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#string\">string</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck011.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_choice.gif\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Choice of Types\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Onsetoffirstreaction\" title=\"The onset of the first known occurrence of a reaction event.\">Onsetoffirstreaction</a><a name=\"AdverseReactionRisk.Data.Onsetoffirstreaction\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Onset of first reaction</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0110.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vline.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_primitive.png\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Primitive Data Type\" class=\"hierarchy\"/> <span title=\"Base StructureDefinition for dateTime Type: A date, date-time or partial date (e.g. just year or year + month).  If hours and minutes are specified, a time zone SHALL be populated. The format is a union of the schema types gYear, gYearMonth, date and dateTime. Seconds must be provided due to schema type constraints but may be zero-filled and may be ignored.                 Dates SHALL be valid dates.\">Onsetoffirstreaction</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#dateTime\">dateTime</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck0100.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vline.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin_end.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_primitive.png\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Primitive Data Type\" class=\"hierarchy\"/> <span title=\"Base StructureDefinition for string Type: A sequence of Unicode characters\">Onsetoffirstreaction</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#string\">string</a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"/></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_datatype.gif\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Reactionmechanism\" title=\"Identification of the underlying physiological mechanism for the adverse reaction.\">Reactionmechanism</a><a name=\"AdverseReactionRisk.Data.Reactionmechanism\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#CodeableConcept\">CodeableConcept</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Reaction mechanism</td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: #F7F7F7\"><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck010.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_reference.png\" alt=\".\" style=\"background-color: #F7F7F7; background-color: inherit\" title=\"Reference to another Resource\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Reactioneventsummary\" title=\"Summary details about each adverse reaction event linked to exposure to the identified 'Substance'.\">Reactioneventsummary</a><a name=\"AdverseReactionRisk.Data.Reactioneventsummary\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..*</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/references.html\">Reference</a>(<a href=\"StructureDefinition-AdverseReactionEvent.html\">Adverse Reaction Event</a>)</td><td style=\"vertical-align: top; text-align : left; background-color: #F7F7F7; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Reaction event summary<br/></td></tr>\r\n<tr style=\"border: 0px #F0F0F0 solid; padding:0px; vertical-align: top; background-color: white\"><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px; white-space: nowrap; background-image: url(tbl_bck000.png)\" class=\"hierarchy\"><img src=\"tbl_spacer.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_blank.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"tbl_vjoin_end.png\" alt=\".\" style=\"background-color: inherit\" class=\"hierarchy\"/><img src=\"icon_primitive.png\" alt=\".\" style=\"background-color: white; background-color: inherit\" title=\"Primitive Data Type\" class=\"hierarchy\"/> <a href=\"StructureDefinition-AdverseReactionRisk-definitions.html#AdverseReactionRisk.Data.Comment\" title=\"Additional narrative about the propensity for the adverse reaction, not captured in other fields.\">Comment</a><a name=\"AdverseReactionRisk.Data.Comment\"> </a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><span style=\"padding-left: 3px; padding-right: 3px; color: white; background-color: red\" title=\"This element must be supported\">S</span></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">0..1</td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\"><a href=\"http://hl7.org/fhir/R4/datatypes.html#string\">string</a></td><td style=\"vertical-align: top; text-align : left; background-color: white; border: 0px #F0F0F0 solid; padding:0px 4px 0px 4px\" class=\"hierarchy\">Comment</td></tr>\r\n<tr><td colspan=\"5\" class=\"hierarchy\"><br/><a href=\"https://build.fhir.org/ig/FHIR/ig-guidance/readingIgs.html#table-views\" title=\"Legend for this format\"><img src=\"data:image/png;base64,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\" alt=\"doco\" style=\"background-color: inherit\"/> Documentation for this format</a></td></tr></table></div>"
  },
  "url" : "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRisk",
  "identifier" : [
    {
      "system" : "https://aehrc.csiro.au/id/archetype_id",
      "value" : "openEHR-EHR-EVALUATION.adverse_reaction_risk.v2"
    }
  ],
  "version" : "0.0.1",
  "name" : "AdverseReactionRisk",
  "title" : "Adverse Reaction Risk",
  "status" : "draft",
  "experimental" : false,
  "date" : "2023-09-11T00:54:09+10:00",
  "publisher" : "CSIRO",
  "contact" : [
    {
      "name" : "CSIRO",
      "telecom" : [
        {
          "system" : "url",
          "value" : "https://aehrc.csiro.au/"
        }
      ]
    },
    {
      "name" : "AU logical models",
      "telecom" : [
        {
          "system" : "url",
          "value" : "https://aehrc.csiro.au/"
        }
      ]
    }
  ],
  "description" : "The Adverse Reaction Risk Logical Model Mindmap is shown below.\n\n<div><img src='data:image/png;base64,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'/></div>\n\nClinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance.\n\n**Purpose**\n\nTo record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances.\n\n**Misuse**\n\nNot to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.\r\n\r\nNot to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. \r\n\r\nNot to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.\r\n\r\nNot to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. \r\n\r\nNot to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.\r\n\r\nNot to be used for recording failed therapy.\r\n\r\nNot to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.\r\n\r\nNot to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions.\n\n**Considerations**\n\nUse to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. \r\n\r\nThis archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\r\n- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or \r\n- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.\r\nIn clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.\r\n\r\nWhere a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.\r\n\r\nIdentification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.\r\n\r\nThis archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.\r\n\r\nUse to record information about the positive presence of the risk of an adverse reaction:\r\n- to support the direct clinical care of an individual; \r\n- as part of a managed adverse reaction or allergy/intolerance list; \r\n- to support the exchange of information about the propensity and events related to adverse reactions; \r\n- to inform adverse reaction reporting; and \r\n- to assist with computerised knowledge-based activities such as clinical decision support and alerts.\r\n\r\nThe risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing.",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code" : "036",
          "display" : "Australia (AUS)"
        }
      ]
    }
  ],
  "fhirVersion" : "4.0.1",
  "kind" : "logical",
  "abstract" : false,
  "type" : "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRisk",
  "baseDefinition" : "http://hl7.org/fhir/StructureDefinition/Base",
  "derivation" : "specialization",
  "snapshot" : {
    "element" : [
      {
        "id" : "AdverseReactionRisk",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0000"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. \r\n\r\nThis archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\r\n- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or \r\n- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.\r\nIn clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.\r\n\r\nWhere a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.\r\n\r\nIdentification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.\r\n\r\nThis archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.\r\n\r\nUse to record information about the positive presence of the risk of an adverse reaction:\r\n- to support the direct clinical care of an individual; \r\n- as part of a managed adverse reaction or allergy/intolerance list; \r\n- to support the exchange of information about the propensity and events related to adverse reactions; \r\n- to inform adverse reaction reporting; and \r\n- to assist with computerised knowledge-based activities such as clinical decision support and alerts.\r\n\r\nThe risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing."
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-misuse",
            "valueString" : "Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.\r\n\r\nNot to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. \r\n\r\nNot to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.\r\n\r\nNot to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. \r\n\r\nNot to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.\r\n\r\nNot to be used for recording failed therapy.\r\n\r\nNot to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.\r\n\r\nNot to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions."
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-purpose",
            "valueString" : "To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk",
        "short" : "Adverse Reaction Risk",
        "definition" : "Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance.",
        "comment" : "**Purpose**\n\nTo record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances.\n\n**Misuse**\n\nNot to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.\r\n\r\nNot to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. \r\n\r\nNot to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.\r\n\r\nNot to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. \r\n\r\nNot to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.\r\n\r\nNot to be used for recording failed therapy.\r\n\r\nNot to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.\r\n\r\nNot to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions.\n\n**Considerations**\n\nUse to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. \r\n\r\nThis archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\r\n- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or \r\n- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.\r\nIn clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.\r\n\r\nWhere a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.\r\n\r\nIdentification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.\r\n\r\nThis archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.\r\n\r\nUse to record information about the positive presence of the risk of an adverse reaction:\r\n- to support the direct clinical care of an individual; \r\n- as part of a managed adverse reaction or allergy/intolerance list; \r\n- to support the exchange of information about the propensity and events related to adverse reactions; \r\n- to inform adverse reaction reporting; and \r\n- to assist with computerised knowledge-based activities such as clinical decision support and alerts.\r\n\r\nThe risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing.",
        "alias" : [
          "reaction"
        ],
        "min" : 0,
        "max" : "*",
        "base" : {
          "path" : "Base",
          "min" : 0,
          "max" : "*"
        },
        "mustSupport" : true,
        "isModifier" : false
      },
      {
        "id" : "AdverseReactionRisk.Protocol",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "protocol"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Protocol",
        "short" : "Protocol",
        "definition" : "@ internal @",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Protocol",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "BackboneElement"
          }
        ],
        "constraint" : [
          {
            "key" : "ele-1",
            "severity" : "error",
            "human" : "All FHIR elements must have a @value or children",
            "expression" : "hasValue() or (children().count() > id.count())",
            "xpath" : "@value|f:*|h:div",
            "source" : "http://hl7.org/fhir/StructureDefinition/Element"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Protocol.id",
        "path" : "AdverseReactionRisk.Protocol.id",
        "representation" : [
          "xmlAttr"
        ],
        "short" : "Unique id for inter-element referencing",
        "definition" : "Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "Element.id",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "extension" : [
              {
                "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fhir-type",
                "valueUrl" : "string"
              }
            ],
            "code" : "http://hl7.org/fhirpath/System.String"
          }
        ],
        "isModifier" : false,
        "isSummary" : false,
        "mapping" : [
          {
            "identity" : "rim",
            "map" : "n/a"
          }
        ]
      },
      {
        "id" : "AdverseReactionRisk.Protocol.extension",
        "path" : "AdverseReactionRisk.Protocol.extension",
        "slicing" : {
          "discriminator" : [
            {
              "type" : "value",
              "path" : "url"
            }
          ],
          "description" : "Extensions are always sliced by (at least) url",
          "rules" : "open"
        },
        "short" : "Additional content defined by implementations",
        "definition" : "May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance  applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension.",
        "comment" : "There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.",
        "alias" : [
          "extensions",
          "user content"
        ],
        "min" : 0,
        "max" : "*",
        "base" : {
          "path" : "Element.extension",
          "min" : 0,
          "max" : "*"
        },
        "type" : [
          {
            "code" : "Extension"
          }
        ],
        "constraint" : [
          {
            "key" : "ele-1",
            "severity" : "error",
            "human" : "All FHIR elements must have a @value or children",
            "expression" : "hasValue() or (children().count() > id.count())",
            "xpath" : "@value|f:*|h:div",
            "source" : "http://hl7.org/fhir/StructureDefinition/Element"
          },
          {
            "key" : "ext-1",
            "severity" : "error",
            "human" : "Must have either extensions or value[x], not both",
            "expression" : "extension.exists() != value.exists()",
            "xpath" : "exists(f:extension)!=exists(f:*[starts-with(local-name(.), \"value\")])",
            "source" : "http://hl7.org/fhir/StructureDefinition/Extension"
          }
        ],
        "isModifier" : false,
        "isSummary" : false,
        "mapping" : [
          {
            "identity" : "rim",
            "map" : "n/a"
          }
        ]
      },
      {
        "id" : "AdverseReactionRisk.Protocol.modifierExtension",
        "path" : "AdverseReactionRisk.Protocol.modifierExtension",
        "short" : "Extensions that cannot be ignored even if unrecognized",
        "definition" : "May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.\n\nModifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).",
        "comment" : "There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.",
        "requirements" : "Modifier extensions allow for extensions that *cannot* be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored.  This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the [definition of modifier extensions](http://hl7.org/fhir/R4/extensibility.html#modifierExtension).",
        "alias" : [
          "extensions",
          "user content",
          "modifiers"
        ],
        "min" : 0,
        "max" : "*",
        "base" : {
          "path" : "BackboneElement.modifierExtension",
          "min" : 0,
          "max" : "*"
        },
        "type" : [
          {
            "code" : "Extension"
          }
        ],
        "constraint" : [
          {
            "key" : "ele-1",
            "severity" : "error",
            "human" : "All FHIR elements must have a @value or children",
            "expression" : "hasValue() or (children().count() > id.count())",
            "xpath" : "@value|f:*|h:div",
            "source" : "http://hl7.org/fhir/StructureDefinition/Element"
          },
          {
            "key" : "ext-1",
            "severity" : "error",
            "human" : "Must have either extensions or value[x], not both",
            "expression" : "extension.exists() != value.exists()",
            "xpath" : "exists(f:extension)!=exists(f:*[starts-with(local-name(.), \"value\")])",
            "source" : "http://hl7.org/fhir/StructureDefinition/Extension"
          }
        ],
        "isModifier" : true,
        "isModifierReason" : "Modifier extensions are expected to modify the meaning or interpretation of the element that contains them",
        "isSummary" : true,
        "mapping" : [
          {
            "identity" : "rim",
            "map" : "N/A"
          }
        ]
      },
      {
        "id" : "AdverseReactionRisk.Protocol.Lastupdated",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0062"
            }
          }
        ],
        "path" : "AdverseReactionRisk.Protocol.Lastupdated",
        "short" : "Last updated",
        "definition" : "Date when the propensity or the reaction event was updated.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Protocol.Lastupdated",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "dateTime"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Protocol.Extension",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0128"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: local information requirements or additional metadata to align with FHIR equivalents."
          }
        ],
        "path" : "AdverseReactionRisk.Protocol.Extension",
        "short" : "Extension",
        "definition" : "Additional information required to capture local content or to align with other reference models/formalisms.",
        "comment" : "**Considerations**\n\nFor example: local information requirements or additional metadata to align with FHIR equivalents.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Protocol.Extension",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "Reference"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "data"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data",
        "short" : "Data",
        "definition" : "@ internal @",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "BackboneElement"
          }
        ],
        "constraint" : [
          {
            "key" : "ele-1",
            "severity" : "error",
            "human" : "All FHIR elements must have a @value or children",
            "expression" : "hasValue() or (children().count() > id.count())",
            "xpath" : "@value|f:*|h:div",
            "source" : "http://hl7.org/fhir/StructureDefinition/Element"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.id",
        "path" : "AdverseReactionRisk.Data.id",
        "representation" : [
          "xmlAttr"
        ],
        "short" : "Unique id for inter-element referencing",
        "definition" : "Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "Element.id",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "extension" : [
              {
                "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fhir-type",
                "valueUrl" : "string"
              }
            ],
            "code" : "http://hl7.org/fhirpath/System.String"
          }
        ],
        "isModifier" : false,
        "isSummary" : false,
        "mapping" : [
          {
            "identity" : "rim",
            "map" : "n/a"
          }
        ]
      },
      {
        "id" : "AdverseReactionRisk.Data.extension",
        "path" : "AdverseReactionRisk.Data.extension",
        "slicing" : {
          "discriminator" : [
            {
              "type" : "value",
              "path" : "url"
            }
          ],
          "description" : "Extensions are always sliced by (at least) url",
          "rules" : "open"
        },
        "short" : "Additional content defined by implementations",
        "definition" : "May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance  applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension.",
        "comment" : "There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.",
        "alias" : [
          "extensions",
          "user content"
        ],
        "min" : 0,
        "max" : "*",
        "base" : {
          "path" : "Element.extension",
          "min" : 0,
          "max" : "*"
        },
        "type" : [
          {
            "code" : "Extension"
          }
        ],
        "constraint" : [
          {
            "key" : "ele-1",
            "severity" : "error",
            "human" : "All FHIR elements must have a @value or children",
            "expression" : "hasValue() or (children().count() > id.count())",
            "xpath" : "@value|f:*|h:div",
            "source" : "http://hl7.org/fhir/StructureDefinition/Element"
          },
          {
            "key" : "ext-1",
            "severity" : "error",
            "human" : "Must have either extensions or value[x], not both",
            "expression" : "extension.exists() != value.exists()",
            "xpath" : "exists(f:extension)!=exists(f:*[starts-with(local-name(.), \"value\")])",
            "source" : "http://hl7.org/fhir/StructureDefinition/Extension"
          }
        ],
        "isModifier" : false,
        "isSummary" : false,
        "mapping" : [
          {
            "identity" : "rim",
            "map" : "n/a"
          }
        ]
      },
      {
        "id" : "AdverseReactionRisk.Data.modifierExtension",
        "path" : "AdverseReactionRisk.Data.modifierExtension",
        "short" : "Extensions that cannot be ignored even if unrecognized",
        "definition" : "May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions.\n\nModifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).",
        "comment" : "There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions.  The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.",
        "requirements" : "Modifier extensions allow for extensions that *cannot* be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored.  This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the [definition of modifier extensions](http://hl7.org/fhir/R4/extensibility.html#modifierExtension).",
        "alias" : [
          "extensions",
          "user content",
          "modifiers"
        ],
        "min" : 0,
        "max" : "*",
        "base" : {
          "path" : "BackboneElement.modifierExtension",
          "min" : 0,
          "max" : "*"
        },
        "type" : [
          {
            "code" : "Extension"
          }
        ],
        "constraint" : [
          {
            "key" : "ele-1",
            "severity" : "error",
            "human" : "All FHIR elements must have a @value or children",
            "expression" : "hasValue() or (children().count() > id.count())",
            "xpath" : "@value|f:*|h:div",
            "source" : "http://hl7.org/fhir/StructureDefinition/Element"
          },
          {
            "key" : "ext-1",
            "severity" : "error",
            "human" : "Must have either extensions or value[x], not both",
            "expression" : "extension.exists() != value.exists()",
            "xpath" : "exists(f:extension)!=exists(f:*[starts-with(local-name(.), \"value\")])",
            "source" : "http://hl7.org/fhir/StructureDefinition/Extension"
          }
        ],
        "isModifier" : true,
        "isModifierReason" : "Modifier extensions are expected to modify the meaning or interpretation of the element that contains them",
        "isSummary" : true,
        "mapping" : [
          {
            "identity" : "rim",
            "map" : "N/A"
          }
        ]
      },
      {
        "id" : "AdverseReactionRisk.Data.Substance",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0002"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Both an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Substance",
        "short" : "Substance",
        "definition" : "Identification of a substance, or substance class, that is considered to put the individual at risk of an adverse reaction event.",
        "comment" : "**Considerations**\n\nBoth an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available.",
        "min" : 1,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Substance",
          "min" : 1,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Activeinactivestatus",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0130"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Activeinactivestatus",
        "short" : "Activeinactivestatus",
        "definition" : "Status about whether the adverse reaction risk statement is active or inactive.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Activeinactivestatus",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "Coding"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Verificationstatus",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0063"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Decision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Verificationstatus",
        "short" : "Verification status",
        "definition" : "Assertion about the certainty of the propensity, or potential future risk, of the identified 'Substance' to cause a reaction.",
        "comment" : "**Considerations**\n\nDecision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Verificationstatus",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "Coding"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Criticality",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0101"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "This can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Criticality",
        "short" : "Criticality",
        "definition" : "An indication of the potential for critical system organ damage or life threatening consequence.",
        "comment" : "**Considerations**\n\nThis can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Criticality",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Category",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0120"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "This data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Category",
        "short" : "Category",
        "definition" : "Category of the identified 'Substance'.",
        "comment" : "**Considerations**\n\nThis data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Category",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Onsetoflastreaction",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0117"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."
          }
        ],
        "path" : "AdverseReactionRisk.Data.Onsetoflastreaction",
        "short" : "Onset of last reaction",
        "definition" : "The date and/or time of the onset of the last known occurrence of a reaction event.",
        "comment" : "**Considerations**\n\nFor example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Onsetoflastreaction",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "dateTime"
          },
          {
            "code" : "string"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Onsetoffirstreaction",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0133"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."
          }
        ],
        "path" : "AdverseReactionRisk.Data.Onsetoffirstreaction",
        "short" : "Onset of first reaction",
        "definition" : "The onset of the first known occurrence of a reaction event.",
        "comment" : "**Considerations**\n\nFor example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Onsetoffirstreaction",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "dateTime"
          },
          {
            "code" : "string"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Reactionmechanism",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0058"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Immune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. \r\n\r\nImmunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. \r\n\r\nIt is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Reactionmechanism",
        "short" : "Reaction mechanism",
        "definition" : "Identification of the underlying physiological mechanism for the adverse reaction.",
        "comment" : "**Considerations**\n\nImmune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. \r\n\r\nImmunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. \r\n\r\nIt is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Reactionmechanism",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Reactioneventsummary",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0129"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Reactioneventsummary",
        "short" : "Reaction event summary",
        "definition" : "Summary details about each adverse reaction event linked to exposure to the identified 'Substance'.",
        "min" : 0,
        "max" : "*",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Reactioneventsummary",
          "min" : 0,
          "max" : "*"
        },
        "type" : [
          {
            "code" : "Reference",
            "targetProfile" : [
              "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionEvent"
            ]
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Comment",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0006"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover."
          }
        ],
        "path" : "AdverseReactionRisk.Data.Comment",
        "short" : "Comment",
        "definition" : "Additional narrative about the propensity for the adverse reaction, not captured in other fields.",
        "comment" : "**Considerations**\n\nFor example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover.",
        "min" : 0,
        "max" : "1",
        "base" : {
          "path" : "AdverseReactionRisk.Data.Comment",
          "min" : 0,
          "max" : "1"
        },
        "type" : [
          {
            "code" : "string"
          }
        ],
        "mustSupport" : true
      }
    ]
  },
  "differential" : {
    "element" : [
      {
        "id" : "AdverseReactionRisk",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0000"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Use to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. \r\n\r\nThis archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\r\n- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or \r\n- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.\r\nIn clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.\r\n\r\nWhere a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.\r\n\r\nIdentification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.\r\n\r\nThis archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.\r\n\r\nUse to record information about the positive presence of the risk of an adverse reaction:\r\n- to support the direct clinical care of an individual; \r\n- as part of a managed adverse reaction or allergy/intolerance list; \r\n- to support the exchange of information about the propensity and events related to adverse reactions; \r\n- to inform adverse reaction reporting; and \r\n- to assist with computerised knowledge-based activities such as clinical decision support and alerts.\r\n\r\nThe risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing."
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-misuse",
            "valueString" : "Not to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.\r\n\r\nNot to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. \r\n\r\nNot to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.\r\n\r\nNot to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. \r\n\r\nNot to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.\r\n\r\nNot to be used for recording failed therapy.\r\n\r\nNot to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.\r\n\r\nNot to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions."
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-purpose",
            "valueString" : "To record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk",
        "short" : "Adverse Reaction Risk",
        "definition" : "Clinical assessment of the propensity for an individual to experience a harmful or undesirable physiological response if exposed, or re-exposed, to a substance.",
        "comment" : "**Purpose**\n\nTo record the clinical assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances.\n\n**Misuse**\n\nNot to be used for recording physiological reactions to physical agents, such as heat, cold, sunlight, vibration, exercise activity, by infectious agents or food contaminants. Use a specific archetype for EVALUATION.problem/diagnosis or CLUSTER.symptom/sign for this purpose.\r\n\r\nNot to be used to record adverse events, including failures of clinical process, interventions or products. For example: abnormal use, incorrect dosage or maladministration of an agent or substance; mislabelling; harm or injury caused by an intervention or procedure; overdose/poisoning etc. Use a specific archetype for the purpose. \r\n\r\nNot to be used to record an adverse reaction where the substance is unknown. Use EVALUATION.problem_diagnosis or CLUSTER.symptom_sign to record as part of the health record until a possible substance is identified.\r\n\r\nNot to be used to record reactions to transfusions of blood products. Use a specific archetype for this purpose. \r\n\r\nNot to be used for recording 'alerts'. Use EVALUATION.precaution, EVALUATION.contraindication or related archetypes for this purpose.\r\n\r\nNot to be used for recording failed therapy.\r\n\r\nNot to be used for the explicit recording of an absence (or negative presence) of a reaction to 'any substances' or to identified substances, for example ‘No known allergies or adverse reactions’ or ‘No known allergies to Penicillin’. Use the EVALUATION.exclusion_global or EVALUATION.exclusion_specific archetypes to express a positive statement of adverse reaction exclusion.\r\n\r\nNot to be used for the explicit recording that no information was able to be obtained about the adverse reaction status of a patient. Use the EVALUATION.absence archetype to record that a positive statement that information was not able to be obtained, for example, if a non-cooperative patient refuses to answer questions.\n\n**Considerations**\n\nUse to record a clinical assessment of a propensity for an adverse reaction upon future exposure to a specified substance or class of substances including, but not limited to, incipients and excipients in medicinal preparations, biological products, metal salts, and organic chemical compounds. \r\n\r\nThis archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\r\n- immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or \r\n- non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities.\r\nIn clinical practice distinguishing between immune-mediated and non-immune-mediated reactions can be difficult. Identification of the type of reaction is not a proxy for seriousness or risk of harm to the patient.\r\n\r\nWhere a propensity is identified, information or evidence about one or more reaction events can be recorded using the CLUSTER.adverse_reaction_event archetype in the 'Reaction event summary' SLOT.\r\n\r\nIdentification of the severity of the manifestation of the reaction, recorded in the CLUSTER.adverse_reaction_event archetype, can inform the 'Criticality' of the adverse reaction risk. For example, experiencing anaphylaxis on first exposure to a substance would warrant setting a 'Criticality' of 'high', due to the high risk that anaphylaxis is likely to recur on second and subsequent exposures.\r\n\r\nThis archetype has been designed to allow the recording of information about a specific substance (amoxycillin, oysters, or bee sting venom) or, alternatively, a class of substance (e.g. Penicillins). If a class of substance is recorded, identification of the exact substance can be recorded on a per-reaction basis using the CLUSTER.adverse_reaction_event archetype.\r\n\r\nUse to record information about the positive presence of the risk of an adverse reaction:\r\n- to support the direct clinical care of an individual; \r\n- as part of a managed adverse reaction or allergy/intolerance list; \r\n- to support the exchange of information about the propensity and events related to adverse reactions; \r\n- to inform adverse reaction reporting; and \r\n- to assist with computerised knowledge-based activities such as clinical decision support and alerts.\r\n\r\nThe risk of an adverse reaction event or manifestation must always propose a causative substance or class of substance. If there is a degree of uncertainty that a specific substance is the cause, the level of uncertainty can be recorded using the ‘Verification status’ data element. If more than one possible substance may have caused a reaction/manifestation, each substance should be recorded using a separate instance of this adverse reaction risk archetype with the ‘Verification status’ set to an initial state of ‘Unconfirmed’ so that adverse reaction checking can be activated in clinical systems. If the substance is later proven not to be causal then the ‘Verification status’ can be modified to ‘Refuted’ - for example, after allergy testing.",
        "alias" : [
          "reaction"
        ],
        "min" : 0,
        "max" : "*",
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Protocol",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "protocol"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Protocol",
        "short" : "Protocol",
        "definition" : "@ internal @",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "BackboneElement"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Protocol.Lastupdated",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0062"
            }
          }
        ],
        "path" : "AdverseReactionRisk.Protocol.Lastupdated",
        "short" : "Last updated",
        "definition" : "Date when the propensity or the reaction event was updated.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "dateTime"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Protocol.Extension",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0128"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: local information requirements or additional metadata to align with FHIR equivalents."
          }
        ],
        "path" : "AdverseReactionRisk.Protocol.Extension",
        "short" : "Extension",
        "definition" : "Additional information required to capture local content or to align with other reference models/formalisms.",
        "comment" : "**Considerations**\n\nFor example: local information requirements or additional metadata to align with FHIR equivalents.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "Reference"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "data"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data",
        "short" : "Data",
        "definition" : "@ internal @",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "BackboneElement"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Substance",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0002"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Both an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Substance",
        "short" : "Substance",
        "definition" : "Identification of a substance, or substance class, that is considered to put the individual at risk of an adverse reaction event.",
        "comment" : "**Considerations**\n\nBoth an individual substance and a substance class are valid entries in 'Substance'. A substance may be a compound of simpler substances, for example a medicinal product. It is strongly recommended that the 'Substance' is coded with a terminology capable of triggering decision support, where possible. For example: Snomed CT, DM+D, RxNorm, NDFRT, ATC, New Zealand Universal List of Medicines and Australian Medicines Terminology. Free text entry should only be used if there is no appropriate terminology available.",
        "min" : 1,
        "max" : "1",
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Activeinactivestatus",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0130"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Activeinactivestatus",
        "short" : "Activeinactivestatus",
        "definition" : "Status about whether the adverse reaction risk statement is active or inactive.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "Coding"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Verificationstatus",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0063"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Decision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Verificationstatus",
        "short" : "Verification status",
        "definition" : "Assertion about the certainty of the propensity, or potential future risk, of the identified 'Substance' to cause a reaction.",
        "comment" : "**Considerations**\n\nDecision support would typically raise alerts for 'Unconfirmed' and 'Confirmed', and ignore a 'Refuted' reaction. Clinical systems may choose not to display Adverse reaction entries with a 'Refuted' status in the Adverse Reaction List. However, 'Refuted' may be useful for reconciliation of the adverse reaction list or when communicating between systems. Some implementations may choose to make this field mandatory. The free text data type will allow for local variation by enabling other value sets to be applied to this data element in a template - in this situation it is recommended that values should be coded using a terminology.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "Coding"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Criticality",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0101"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "This can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Criticality",
        "short" : "Criticality",
        "definition" : "An indication of the potential for critical system organ damage or life threatening consequence.",
        "comment" : "**Considerations**\n\nThis can be regarded as a predictive judgement of a 'worst case scenario'. In most contexts 'Low' would be regarded as the default value.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Category",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0120"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "This data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Category",
        "short" : "Category",
        "definition" : "Category of the identified 'Substance'.",
        "comment" : "**Considerations**\n\nThis data element has been included because it is currently being captured in some clinical systems. This data can be derived from the Substance where coding systems are used, and is effectively redundant in that situation.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Onsetoflastreaction",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0117"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."
          }
        ],
        "path" : "AdverseReactionRisk.Data.Onsetoflastreaction",
        "short" : "Onset of last reaction",
        "definition" : "The date and/or time of the onset of the last known occurrence of a reaction event.",
        "comment" : "**Considerations**\n\nFor example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "dateTime"
          },
          {
            "code" : "string"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Onsetoffirstreaction",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0133"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year."
          }
        ],
        "path" : "AdverseReactionRisk.Data.Onsetoffirstreaction",
        "short" : "Onset of first reaction",
        "definition" : "The onset of the first known occurrence of a reaction event.",
        "comment" : "**Considerations**\n\nFor example: the actual date and/or time of onset; the interval of time during which the onset occurred; the age of the individual at the time of the onset; or the duration of time since the onset occurred. A partial date is valid, using the DV_DATE_TIME data type, to record only a year.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "dateTime"
          },
          {
            "code" : "string"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Reactionmechanism",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0058"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "Immune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. \r\n\r\nImmunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. \r\n\r\nIt is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute."
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Reactionmechanism",
        "short" : "Reaction mechanism",
        "definition" : "Identification of the underlying physiological mechanism for the adverse reaction.",
        "comment" : "**Considerations**\n\nImmune-mediated responses have been traditionally regarded as an indicator for escalation of significant future risk. Contemporary knowledge suggests that some reactions previously thought to be immune are actually non-immune and still carry life threatening risk. \r\n\r\nImmunological testing may provide supporting evidence for the mechanism and causative substance , but no tests are 100% sensitive or specific for a sensitivity. \r\n\r\nIt is acknowledged that most clinicians will NOT be able to distinguish the mechanism of any specific reaction. However this data element is included because many legacy systems have captured this attribute.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "CodeableConcept"
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Reactioneventsummary",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0129"
            }
          },
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-display-hint",
            "valueString" : "orientation:right"
          }
        ],
        "path" : "AdverseReactionRisk.Data.Reactioneventsummary",
        "short" : "Reaction event summary",
        "definition" : "Summary details about each adverse reaction event linked to exposure to the identified 'Substance'.",
        "min" : 0,
        "max" : "*",
        "type" : [
          {
            "code" : "Reference",
            "targetProfile" : [
              "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionEvent"
            ]
          }
        ],
        "mustSupport" : true
      },
      {
        "id" : "AdverseReactionRisk.Data.Comment",
        "extension" : [
          {
            "url" : "http://hl7.org/fhir/StructureDefinition/elementdefinition-identifier",
            "valueIdentifier" : {
              "system" : "https://aehrc.csiro.au/id/archetype_id/openEHR-EHR-EVALUATION.adverse_reaction_risk.v2",
              "value" : "at0006"
            }
          },
          {
            "url" : "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString" : "For example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover."
          }
        ],
        "path" : "AdverseReactionRisk.Data.Comment",
        "short" : "Comment",
        "definition" : "Additional narrative about the propensity for the adverse reaction, not captured in other fields.",
        "comment" : "**Considerations**\n\nFor example: including reason for flagging a 'Criticality' of 'High risk'; and instructions related to future exposure or administration of the Substance, such as administration within an Intensive Care Unit or under corticosteroid cover.",
        "min" : 0,
        "max" : "1",
        "type" : [
          {
            "code" : "string"
          }
        ],
        "mustSupport" : true
      }
    ]
  }
}

XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.